BioTime (NYSE MKT, TASE: BTX) priced a public offering of 9,615,385 common shares at a price of $2.60 each for gross proceeds of about $25-million.Read More
An investigator-led clinical trial has successfully treated its first patient in a study of BioTime’s (NYSE MKT: BTX) Premvia as a carrier for stromal vascular fraction cells (SVF) for the treatment of age-related volume loss in the face.Read More
RBC Capital Markets upgraded CRH Medical (TSX:CRH; NYSE MKT:CRHM) to “outperform” from “sector perform” but lowered its price target to $6 (Canadian) from $8.50. The stock closed at $4.07 on July 20.Read More
BioTime (NYSE MKT:BTX) has created AgeX Therapeutics, which will consolidate certain BioTime subsidiaries and programs in the field of interventional gerontology.Read More
BioTime (NYSE MKT:BTX) is expanding its ongoing Phase 1/2a clinical trial for OpRegen in the advanced dry form of AMD by naming the first two sites that will treat patients in the U.S.Read More
BioTime (NYSE MKT, TASE:BTX) has closed a public offering of 7,453,704 common shares, including 972,222 shares in connection with the exercise in full of an underwriters’ over allotment option, at a price of $2.70 a share for gross proceeds of about $20.1-million.Read More
BioTime (NYSE MKT:BTX) has appointed Stephana Patton as general counsel, a newly created position. Reporting in her new role to Adi Mohanty, co-CEO, Dr. Patton will oversee all legal matters at the company.Read More
BioTime (NYSE MKT:BTX) has acquired global rights to ophthalmology-related intellectual property assets from the University of Pittsburgh’s Medical Center, via the school’s Innovation Institute.Read More
Roth Capital Partners resumed coverage of Palatin Technologies (NYSE MKT: PTN), AmpliPhi Biosciences (NYSE MKT:APHB) and Pharming Group NV (OTC:PHGUF) with “buy” and price targets of $1.50, $3 and €1.50, respectively.Read More
RBC Capital Markets initiated coverage of CRH Medical (NYSE MKT:CRHM; TSX:CRH) with an “outperform” rating and price target of $6.50 (Canadian). The stock closed at $5.50 on Wednesday.
Analyst Doug Miehm writes that CRH has leveraged its long-standing GI physician relationships and expertise to acquire anesthesiology service businesses in the GI space.Read More
Ladenburg Thalmann has initiated coverage of BioTime (NYSE MKT, TASE:BTX) with a “buy” rating and $6 price target. The stock closed at $3.59 on Thursday.
“We view BioTime as roughly halfway through a restructuring designed to unlock shareholder value through separation of non-core assets and accelerated development of the company's cell therapy programs in ophthalmetry, aesthetics and orthopedics,” writes analyst Kevin DeGeeter.Read More
Roth Capital Partners initiated coverage of Actinium Pharmaceuticals (NYSE MKT:ATNM) with a “buy” rating and $5 price target. The stock closed at $1.66 on Wednesday.
“We believe it is an opportune time to explore the investment case of Actinium based on the late-stage nature of the lead asset, addressing unmet medical needs, clinical data in hand, and a broad set of upcoming catalysts,” writes analyst Joseph Pantginis.Read More
Nobilis Health Corp. (NYSE MKT:HLTH; TSX:NHC) reported revenue of $61.9-million for the second quarter, an increase of 27% from a year ago. In addition, net income increased to $4.8 million from $0.4 million and Adjusted EBITDA increased 23%.Read More
Can-Fite BioPharma’s (NYSE MKT:CANF; TASE:CFBI) subsidiary, OphthaliX (OTC:OPLI) released top-line results from its Phase 2 clinical trial of CF101 for the treatment of glaucoma.
No statistically significant differences were found between the CF101 treated group and the placebo group in the primary endpoint of lowering intra ocular pressure (IOP). High IOP is a characteristic of glaucoma. CF101 was found to have a favorable safety profile and was well tolerated.Read More
Leerink Partners has launched coverage of Axovant Sciences (NYSE MKT:AXON) with an “outperform” rating and $22 price target. The stock closed at $13.15 on Monday.
“We see Axovant as a compelling risk/reward play with three key shots on goal for lead products: RVT-101 (5HT6 antagonist) and nelotanserin (5HT2a inverse agonist), and see long-term upside to the stock if just one of these – Alzheimer’s Disease (AD), Dementia with Lewy Bodies, or hallucinations in DLB/Parkinson’s Disease Dementia – were to succeed,” writes analyst Paul Mattels.Read More
Roth Capital Partners has adjusted its price target for DelMar Pharmaceuticals (OTCQX:DMPID) to $12 from $3 after the company’s 1-for-4 reverse stock split. The stock closed at $5.41 on Friday.
Analyst Joseph Pantginis writes that the company’s net equity and operating funds are now sufficient to meet the goal of up listing to a senior exchange, either NASDAQ or NYSE-MKT, shortly.Read More
Nobilis Health (NYSE MKT:HLTH; TSX:NHC) has appointed Marcos Rodriguez as chief accounting officer.
Mr. Rodriguez brings over 17 years of diversified accounting experience to the company. Prior to joining Nobilis, he served for five years as director in complex financial reporting and enterprise risk at Opportune LLP, and 11 years at Deloitte & Touche as audit senior manager in audit & enterprise risk services.Read More
Senseonics Holdings (NYSE-MKT:SENS) has received CE Mark approval for its Eversense Continuous Glucose Monitoring (CGM) System.
“The CE Mark approval is a significant accomplishment for Senseonics as this application required rigorous regulatory review against high clinical and safety standards,” Dr. Tim Goodnow, CEO and president, said in a statement.Read More
First quarter revenue for Nobilis Health (NYSE MKT:HLTH; TSX:NHC) rose 35% to a record $51.3-million, driven by increased case flow and a higher average revenue per case.
In the first quarter, we invested heavily in new technology and infrastructure to support our forecasted growth in 2016,” CEO, Harry Fleming, said in a statement.Read More
The FDA has advised TransEnterix (NYSE MKT:TRXC) that its SurgiBot System does not meet the criteria for substantial equivalence based on the data and information submitted by the company in its 510(k) submission.
“The FDA’s decision is extremely disappointing. We are in the process of reviewing all aspects of the FDA’s communication,” Todd Pope, president and CEO, said in a statement.Read More